Clopidogrel treatment — Competitive Intelligence Brief

Clopidogrel treatment (Clopidogrel treatment) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: P2Y12 receptor antagonist / Thienopyridine antiplatelet agent. Area: Cardiovascular.

marketed P2Y12 receptor antagonist / Thienopyridine antiplatelet agent P2Y12 receptor Cardiovascular Small molecule

Target snapshot

Clopidogrel treatment (Clopidogrel treatment) — VA Office of Research and Development. Clopidogrel inhibits platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor on platelets.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Clopidogrel treatment TARGET	Clopidogrel treatment	VA Office of Research and Development	marketed	P2Y12 receptor antagonist / Thienopyridine antiplatelet agent	P2Y12 receptor
Switch ticagrelor to clopidogrel	Switch ticagrelor to clopidogrel	The First Affiliated Hospital with Nanjing Medical University	marketed	P2Y12 receptor antagonist; antiplatelet agent	P2Y12 receptor
P2Y12 Receptor Antagonist	P2Y12 Receptor Antagonist	Fu Wai Hospital, Beijing, China	marketed	P2Y12 receptor antagonist	P2Y12 receptor
Crushed ticagrelor, morphine,metoclopramide	Crushed ticagrelor, morphine,metoclopramide	Collegium Medicum w Bydgoszczy	marketed	Antiplatelet agent + opioid analgesic + antiemetic (combination therapy)	P2Y12 receptor (ticagrelor); mu opioid receptors (morphine); dopamine D2 receptors (metoclopramide)
Standard-DAPT of Ticagrelor plus aspirin	Standard-DAPT of Ticagrelor plus aspirin	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	Dual antiplatelet therapy (DAPT); P2Y12 inhibitor + cyclooxygenase inhibitor	P2Y12 receptor (ticagrelor); cyclooxygenase-1 (aspirin)
ASA plus Clopidogrel	ASA plus Clopidogrel	Texas Cardiac Arrhythmia Research Foundation	marketed	Dual antiplatelet agent	COX-1 (aspirin); P2Y12 receptor (clopidogrel)
Prasugrel loading	Prasugrel loading	Azienda Policlinico Umberto I	marketed	P2Y12 receptor antagonist (thienopyridine)	P2Y12 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (P2Y12 receptor antagonist / Thienopyridine antiplatelet agent class)

1. Azienda Policlinico Umberto I · 1 drug in this class
2. Hospital Central San Luis Potosi, Mexico · 1 drug in this class
3. Sanofi · 1 drug in this class
4. Seung-Jung Park · 1 drug in this class
5. Stiftung Institut fuer Herzinfarktforschung · 1 drug in this class
6. US Department of Veterans Affairs · 1 drug in this class
7. University of Pecs · 1 drug in this class
8. VA Office of Research and Development · 1 drug in this class